SDC1 and plasma cell myeloma: The results show that the CD38-specific HLE-nano-BiKEs and daratumumab induced NK92 hCD16 cell mediated cytolysis of primary CD138+/CD38+ MM cells with similar efficacies, while the isotype-control HLE-nano-BiKE co did not induce NK92 hCD16 cell mediated death of primary myeloma cells.